ALBUQUERQUE, N.M.--(BUSINESS WIRE)--In the monthly President’s Column posted Monday, March 14, at www.biomoda.com, cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) reported on its optimization research for the CyPath® assay now that the pilot clinical study has been completed.
